Market Overview

UPDATE: Ironwood Reports Analysis Found that Patients Treated with Lesinurad Plus Allopurinol in CLEAR 1 and CLEAR 2 trials who Continued Treatment in the CLEAR Extension Study, Maintained Target sUA Levels over Full Two Years

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: Fintech

 

Related Articles (IRWD)